Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics Reports Second Quarter 2024 Financial Results
04:00pm, Thursday, 08'th Aug 2024
Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten; Company Has Initiated Rolling NDA Submission
Cytokinetics Announces Call for Proposals for Corporate Giving Program
07:30am, Tuesday, 30'th Jul 2024
Program Augments Existing Patient Advocacy and Professional Society Donations to Non-Profit Organizations Aligned with Corporate Values
Cytokinetics to Announce Second Quarter Results on August 8, 2024
04:00pm, Thursday, 25'th Jul 2024
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
11:08am, Thursday, 25'th Jul 2024
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Wednesday, 03'rd Jul 2024
SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of 48,4
7 Biotech Stocks to Boost Your Portfolio to Peak Health
02:11pm, Wednesday, 26'th Jun 2024
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
07:30am, Monday, 17'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the p
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 04'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of 53,41
Cytokinetics to Participate in June Investor Conferences
04:00pm, Wednesday, 29'th May 2024
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferenc
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
02:45pm, Wednesday, 29'th May 2024
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t
Cytokinetics Announces Closing of Public Offering of Common Stock
04:00pm, Tuesday, 28'th May 2024
SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,9
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
12:15pm, Friday, 24'th May 2024
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
Cytokinetics Announces Pricing of Public Offering of Common Stock
11:30pm, Wednesday, 22'nd May 2024
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its common
NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a stra
Cytokinetics Announces Proposed Public Offering of Common Stock
04:02pm, Wednesday, 22'nd May 2024
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 milli
